481 related articles for article (PubMed ID: 1586377)
1. Effects of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine on platelet aggregation and thrombosis in experimental animals.
Momo K; Someya K; Tachiiri T; Mitsuoka Y; Nakamura K; Imai S; Ino T; Ohkubo H
Arzneimittelforschung; 1992 Jan; 42(1):32-9. PubMed ID: 1586377
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet effects of 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine in relation to its disposition in rats, rabbits and dogs.
Ohmuro S; Sasahara T; Taga F; Ohkubo H; Uchida H
Arzneimittelforschung; 1992 Jan; 42(1):43-7. PubMed ID: 1586379
[TBL] [Abstract][Full Text] [Related]
3. [Clinical and preclinical pharmacology of KC-764, a novel antiplatelet agent].
Yoshioka M; Soga T; Mase K; Yasunaga K
Nihon Rinsho; 1992 Feb; 50(2):379-84. PubMed ID: 1613994
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and antiplatelet effects of the new antithrombotic agent aspalatone with low ulcerogenicity.
Han BH; Suh DY; Yang HO; Park YH; Kang YH; Kim YC
Arzneimittelforschung; 1994 Oct; 44(10):1122-6. PubMed ID: 7818584
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine on myocardial damage due to coronary occlusion and reperfusion in rabbit.
Ohmuro S; Tsukada Y; Taga F; Ohkubo H; Uchida H
Arzneimittelforschung; 1992 Jan; 42(1):39-42. PubMed ID: 1586378
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine in laboratory animals.
Komuro M; Hori W; Hotta M; Saitoh S; Ishida R; Uchida H
Arzneimittelforschung; 1992 Jan; 42(1):55-9. PubMed ID: 1586381
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate.
Karasawa A; Kawakage M; Shirakura S; Higo K; Kubo K; Ohshima E; Obase H
Arzneimittelforschung; 1991 Dec; 41(12):1230-6. PubMed ID: 1840011
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of tetrahydroberberine on platelet aggregation and thrombosis.
Xuan B; Wang W; Li DX
Zhongguo Yao Li Xue Bao; 1994 Mar; 15(2):133-5. PubMed ID: 8010106
[TBL] [Abstract][Full Text] [Related]
9. [Effect of a new thromboxane A2 antagonist, S-145, on platelet aggregation].
Kakushi H; Shike T; Uchida K
Nihon Yakurigaku Zasshi; 1989 Mar; 93(3):171-8. PubMed ID: 2731807
[TBL] [Abstract][Full Text] [Related]
10. Effect of vintoperol on platelet aggregation and experimental thrombosis.
Csomor K; Kárpáti E
Arzneimittelforschung; 1994 Jan; 44(1):36-40. PubMed ID: 8135876
[TBL] [Abstract][Full Text] [Related]
11. Effect of cilostazol on platelet aggregation and experimental thrombosis.
Kimura Y; Tani T; Kanbe T; Watanabe K
Arzneimittelforschung; 1985; 35(7A):1144-9. PubMed ID: 4074426
[TBL] [Abstract][Full Text] [Related]
12. Hydroxychavicol, a novel betel leaf component, inhibits platelet aggregation by suppression of cyclooxygenase, thromboxane production and calcium mobilization.
Chang MC; Uang BJ; Tsai CY; Wu HL; Lin BR; Lee CS; Chen YJ; Chang CH; Tsai YL; Kao CJ; Jeng JH
Br J Pharmacol; 2007 Sep; 152(1):73-82. PubMed ID: 17641677
[TBL] [Abstract][Full Text] [Related]
13. Antiplatelet and antithrombotic activities of Korean Red Ginseng.
Yu JY; Jin YR; Lee JJ; Chung JH; Noh JY; You SH; Kim KN; Im JH; Lee JH; Seo JM; Han HJ; Lim Y; Park ES; Kim TJ; Shin KS; Wee JJ; Park JD; Yun YP
Arch Pharm Res; 2006 Oct; 29(10):898-903. PubMed ID: 17121186
[TBL] [Abstract][Full Text] [Related]
14. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets.
Horie S; Yamada M; Satoh M; Noritake S; Hiraishi S; Kizaki K; Kurusu O; Nakahara T; Ishii H; Kazama M
Biol Pharm Bull; 1997 Jun; 20(6):625-31. PubMed ID: 9212979
[TBL] [Abstract][Full Text] [Related]
15. In vitro antiplatelet profiles of the new thromboxane synthetase inhibitor sodium 2-(1-imidazolylmethyl)-4,5-dihydrobenzo[b]thiophene-6-carboxylate.
Asai F; Ito T; Ushiyama S; Matsuda K; Oshima T
Arzneimittelforschung; 1991 May; 41(5):506-10. PubMed ID: 1898421
[TBL] [Abstract][Full Text] [Related]
16. The anti-platelet actions of FR122047, a novel cyclooxygenase inhibitor.
Dohi M; Sakata Y; Seki J; Namikawa Y; Fujisaki J; Tanaka A; Takasugi H; Motoyama Y; Yoshida K
Eur J Pharmacol; 1993 Oct; 243(2):179-84. PubMed ID: 8276067
[TBL] [Abstract][Full Text] [Related]
17. Combined arachidonic acid and ADP platelet inhibition maximizes patency of small-diameter vascular grafts.
Valentin LI; Sicard GA; Freeman MB; Allen BT; McGoff MA; Anderson CB
Surgery; 1988 Aug; 104(2):178-84. PubMed ID: 3135624
[TBL] [Abstract][Full Text] [Related]
18. [Effects of 3-n-butylphthalide on thrombosis formation and platelet function in rats].
Xu HL; Feng YP
Yao Xue Xue Bao; 2001 May; 36(5):329-33. PubMed ID: 12584852
[TBL] [Abstract][Full Text] [Related]
19. Effect of 1-methyl-2-mercapto-5-(3-pyridyl)-imidazole (KC-6141) on rabbit platelet aggregation in vitro and rat platelet retention.
Umetsu T; Kato T
Thromb Haemost; 1978 Feb; 39(1):167-76. PubMed ID: 580491
[TBL] [Abstract][Full Text] [Related]
20. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active.
Cook NS; Bruttger O; Pally C; Hagenbach A
Thromb Haemost; 1993 Nov; 70(5):838-47. PubMed ID: 8128443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
